100-Year Human Aging Study Aims to Validate Surrogate Endpoints in Longevity Medicine
The study will assess whether multi-system health measurements can predict mortality and serious diseases.
Phase III
Geriatrics / Aging
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The 100-Year Human Aging Study aims to validate surrogate endpoints that could revolutionize drug development in aging-related therapies. Success in this trial may lead to the identification of new biomarkers, significantly impacting clinical strategies and research directions in geriatrics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor enrollment numbers and interim results for predictive health measurements and their correlation with mortality.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.